India-AID initiative proposed to address global health challenges amid dismantling of key international aid organizations.

The project will be an extension of the CDSCO and NIHFW's ongoing training programmes with drug inspectors from the central ...

The collaboration, which is reportedly a first of its kind in southern India, aims to equip students with smart manufacturing ...

Billionaire entrepreneur and Cost Plus Drugs co-founder Mark Cuban won't have to raise medicine prices, as Trump’s new reciprocal tariffs on India exempt the pharmaceutical sector. What Happened ...

The Trump administration's decision to exempt tariffs on Indian pharma imports brings relief to a $9 billion-plus US export market, highlighting India's key role in providing affordable generic ...

The session highlighted existing policy support mechanisms and upcoming opportunities under the PRIP scheme aimed at ...

The US pharma import market splits into high-value patented drugs, mostly from Europe (Ireland, Germany, Switzerland), and lower-value generics, led by India, China, and Mexico, where India dominates.

On Business Today TV’s Market Today Show, Mayuresh Joshi, Head of Equity Research at William O’Neil India, explains why pharma remains a compelling bet even beyond the current global shake-up.

Currently, too, the US does not impose any tariff on pharma product imports from India. The US is India’s largest export market for pharmaceutical goods, so the exemption brings huge relief to ...

The company said that ZAMTO Cell is designed to target both CD19 and CD20, which could improve treatment efficacy.

Interestingly, U.S. President Donald Trump announced a 26% reciprocal tariff on India. The pharmaceutical industry, however, was exempted from these new levies, as per the fact sheet released by ...